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Abstract 
Purpose: Fidaxomicin use in real-world clinical practice, especially for severe Clostridium difficile infection (CDI), is 
mainly based on single-center observational studies. The purpose of this pharmacoepidemiology study was to assess 
outcomes of patients given fidaxomicin based on episode number and use of concomitant antibiotics.
Methods: Fidaxomicin use over time across included hospitals in the United States was assessed using a large inpa-
tient drug utilization database. A multicenter retrospective chart review was also conducted of hospitalized patients 
with CDI that received fidaxomicin between 2011 and 2013. Fidaxomicin utilization and clinical outcomes were strati-
fied by use of fidaxomicin for first or second episode (early episodes) versus greater than or equal to episodes (later 
episodes).
Results: The overall fidaxomicin use rate was 2.16 % which increased from 0.22 % in the last two quarters of 2011 to 
3.16 % in the first two quarters of 2013. A total of 102 hospitalized patients that received fidaxomicin from 11 hospitals 
were identified in the multicenter study. Sixty-nine patients received fidaxomicin for early (68 % with severe CDI) and 
33 received for later episodes. The majority of patients received other CDI therapy including 61 patients (88 %) for 
early episodes and 27 (82 %) for later episodes. Concomitant non-CDI antibiotics were received by 48 patients (47 %). 
Rates of clinical outcomes were similar regardless of CDI episode.
Conclusion: This study demonstrated a slow but steady increase in fidaxomicin utilization over time; most of which 
was combined with other systemic antibiotics. Antimicrobial stewardship teams should provide guidance on appro-
priate use of fidaxomicin to optimize therapy and assess the need to continue other antibiotics during CDI treatment.
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Background
According to the Centers for Disease Control and Pre-
vention (CDC), the annual incidence of CDI in the 
United States exceeds 500,000 hospitalized cases with 
29,000 deaths (Lessa et  al. 2015). Treatment options 
for CDI are limited. Metronidazole and oral vancomy-
cin have been utilized as the mainstay therapy for CDI 
(Kelly and LaMont 2008; Cohen et  al. 2010). However, 
morbidity and mortality including the recurrence of CDI 
continues to be a major concern with recurrence rate up 
to 25  % after discontinuation of treatment (McFarland 
et  al. 1999). Moreover, patients with at least one recur-
rence have a higher probability of experiencing further 
recurrences (Sheitoyan-Pesant et  al. 2016). CDI is also 
associated with increased healthcare costs due to longer 
hospitalizations and re-hospitalizations (Lawrence et  al. 
2007; Kyne et al. 2002).
Fidaxomicin, a narrow spectrum macrocyclic anti-
biotic, displays many favorable qualities including 
inhibition of spore formation (Babakhani et  al. 2012), 
preservation of intestinal microbiota (Louie et al. 2012), 
and reduced acquisition of VRE and candida in patients 
treated with fidaxomicin (Nerandzic et  al. 2012). In 
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two, large phase III studies, fidaxomicin was shown to 
decrease recurrent CDI compared to oral vancomycin in 
patients given the drug during their first occurrence or 
first recurrence of CDI disease (Louie et al. 2011; Cornely 
et  al. 2012a, b; Crook et  al. 2012). The current practice 
guidelines by the Society for Healthcare Epidemiology of 
America (SHEA) and Infectious Disease Society of Amer-
ica (IDSA) 2010 clinical practice guidelines (Cohen et al. 
2010) was published prior to the Food and Drug Admin-
istration (FDA) approval of fidaxomicin. The European 
Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) guidelines have mentioned fidaxomicin as one 
of the mainstay CDI therapy and is recommended as one 
of the options for initial, non-severe CDI, initial, severe 
CDI, first recurrent CDI, and in patients at a risk for 
recurrent CDI based on limited evidence (Debast et  al. 
2014).
A case study published after its approval reported 
limited benefit of fidaxomicin when used for multi-
ple recurrent CDI (Orenstein 2012). Two other studies 
have demonstrated positive benefits on the use of fidax-
omicin using a pre-defined protocol (Goldenberg et  al. 
2016; Gallagher et al. 2015). Despite these findings, there 
seems to be a lack of consensus on the optimal time to 
utilize fidaxomicin for CDI management. Furthermore, 
data regarding fidaxomicin utilization in real-world clini-
cal practice. The objective of this study was to evaluate 
fidaxomicin use nationwide in the real-world clinical 
setting. The specific aims of the study was (1) to evalu-
ate fidaxomicin use and overall utilization rate stratified 
by regions, hospital location, and hospital type and CDI 
therapy utilization in the United States; (2) to evaluate 
fidaxomicin use based on CDI episode number, use of 
other CDI therapy and concomitant non-CDI antibiotic 
use.
Methods
The use of fidaxomicin was assessed using a nationally 
representative database and a multisite, chart review 
study of all patients receiving fidaxomicin. For spe-
cific aim 1, the Premier Perspective Database (Safavi 
et al. 2014) was used to identify patients with CDI. Pre-
mier Perspective Database is a largest inpatient drug 
utilization database, consists of data from a network 
of approximately 3400 United States hospitals, includ-
ing >45 million inpatients and >200 million outpatients. 
Data from 372 hospitals contain date-stamp log of all 
billing files that includes drug billing data at the indi-
vidual patient level. The database encompasses events 
during hospitalizations such as diagnoses and medica-
tion administration information directly from electronic 
health records. Each encounter of a patient is given a 
unique identifier. Data collection included information 
from the third quarter of 2011 to the second quarter 
of 2013. Data from CDI patients based on ICD-9 code 
(008.45); type of Clostridium difficile testing; number of 
patients that received fidaxomicin; location of hospital 
(rural vs. urban); hospital type (teaching vs. non-teach-
ing); length of hospital stay (in days); duration of fidax-
omicin therapy; use of other CDI antibiotics for the same 
episode (metronidazole, vancomycin, rifaximin); and 
basic demographics such as age, gender, and race were 
collected.
For specific aim 2, a multicenter review of each hos-
pital’s electronic health record was conducted. Partici-
pating hospitals collected data on adult patients (age 
>18 years) with CDI that received fidaxomicin between 
June 2011 and June 2013. Eligible participants were 
identified through the practice-based research network 
of making a difference in Infectious Diseases (MAD-
ID) (http://mad-id.org/the-mad-id-research-network/). 
CDI was defined as positive fecal C. difficile toxin EIA 
or PCR test plus diarrhea and/or other signs and symp-
toms of CDI. The first documented occurrence of CDI 
was classified as CDI episode 1 and subsequent epi-
sodes were labeled as 2, 3, 4, 5, etc. The severity of CDI 
as mild-moderate versus severe was determined for 
patients with first or second episode of CDI. A case of 
CDI was considered severe if admitted to an intensive 
care unit (ICU), presence of pseudomembranous colitis 
based on colonoscopy or presence of any two of the fol-
lowing parameters such as age >60  years, temperature 
>38.3  °C, albumin <2.5  mg/dL, or WBC >15,000  cells/
mm3 (Zar et  al. 2007). Details regarding fidaxomicin 
regimen, standard regimen (200 mg PO twice a day) or 
a different regimen along with start and stop dates of 
fidaxomicin were recorded. The use of other CDI ther-
apy for the same CDI episode in which fidaxomicin was 
utilized was categorized as subsequent, subsequent and 
combination, or combination therapy. Subsequent CDI 
therapy was switching to another CDI therapy for the 
management of same CDI episode. A change to a com-
bination therapy in which one agent utilized was fidax-
omicin after starting on ≥1 CDI therapy was labeled 
as subsequent and combination. Combination therapy 
included initiation of fidaxomicin plus another CDI 
therapy at the same time. The use of non-CDI antibiot-
ics received during the CDI therapy with fidaxomicin, 
concomitant non-CDI antibiotics, was documented 
as a dichotomous variable. The utilization of concomi-
tant proton-pump inhibitors, histamine-2 (H2) recep-
tor antagonist, and immunosuppressant agents such 
as any systemic steroids, tacrolimus, mycophenolate, 
sirolimus, cyclosporine, chemotherapy agent was also 
documented. For patients that received multiple epi-
sodes of fidaxomicin, data from the first documented 
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use of fidaxomicin for the patient at the institution was 
primarily collected. Episode of fidaxomicin use was 
stratified by first or second episode (early episodes) and 
compared to greater than or equal to three episodes 
(later episodes).
Clinical cure was defined as cure documented in the 
health electronic record or discharge to home or dis-
charge to a site that requires resolution of diarrhea 
prior to admission. Other clinical outcomes including 
recurrent CDI, re-hospitalization and all-cause mor-
tality within 90-days after the initiation of fidaxomicin 
use were evaluated. Another CDI episode after initial 
resolution of CDI episode based on positive fecal C. dif-
ficile toxin EIA or PCR test and/or signs/symptoms of 
CDI was defined as recurrent CDI. Re-hospitalization 
was any re-admission to the index hospital. CDI recur-
rence during the re-hospitalization was considered CDI-
related re-hospitalization and all other re-hospitalization 
was due to other co-morbidities as a primary reason for 
re-hospitalization.
Ethics, consent, and permissions
The study was approved by institutional review board at 
the University of Houston (CPHS:2365) and each par-
ticipating site. A waiver of consent was granted due to 
the retrospective, de-identified nature of the data collec-
tion. All data were reported in aggregate and individual 
patient data were not reported.
Data analyses
Using the Premier database, the overall fidaxomicin use 
(%) was determined by dividing the number of patients 
that received fidaxomicin by the total number of CDI 
patients during the given time period. The fidaxomicin 
use (%) data was stratified by geographic region; West, 
Mid-West, Northeast and South. Fidaxomicin use was 
also compared by hospital variables (hospital location in 
rural versus urban area and hospital type, teaching ver-
sus non-teaching hospitals). Descriptive statistics used to 
evaluate characteristics of the cohort that received fidax-
omicin. The average duration of fidaxomicin therapy and 
average length of hospital stay (in days) per the number of 
patients that received fidaxomicin were evaluated among 
this cohort. Chi squared test was used for inferential sta-
tistics of categorical data. Two-tailed tests were used and 
a p value <0.05 was considered significant. Using data 
from the multicenter, chart review study, treatment pat-
terns of fidaxomicin in relation to other CDI antibiot-
ics were assessed. Demographics, formulary status, and 
study objectives were tabulated and summarized. Usage 
of fidaxomicin was stratified by episodes and usage pat-
terns and outcomes were reported globally as well as by 
episode number.
Results
A total of 474 patients received fidaxomicin among 
21,924 patients with CDI diagnosis based on the ICD-9 
code 008.45 for intestinal infection with CDI. The over-
all use rate of fidaxomicin among all patients with CDI 
was 2.16  % (Table  1). The fidaxomicin utilization rates 
increased from 0.22 % in the last two quarters of 2011 to 
3.6 % in the first two quarters of 2013 (p < 0.0001). Strati-
fied by geographic regions, fidaxomicin utilization rate 
ranged from 1.91 to 2.51  % with small variations noted 
among the regions (West region having the highest rate 
and the Northeast region with the lowest rate). Out of 
2577 patients with CDI in the rural area hospitals, 38 
patients (1.47  %) received fidaxomicin compared to 436 
of 19,347 patients (2.25  %) in the urban area hospitals 
(p = 0.01). Fidaxomicin use rates were similar for teach-
ing (2 %) and non-teaching (2.27 %) (p = 0.18).
Out of the 474 patients that received fidaxomicin, two 
were excluded from this analysis as they were under the 
age of 18 years. The average age of the 472 patients that 
received fidaxomicin was 70 ±  15  years and 65  % were 
females. Three-hundred seventy-five (79.4 %) were Cau-
casians, 10.6  % were African-American and 10  % were 
other. The majority of patients had CDI listed as the pri-
mary (44  %) or secondary (51  %) diagnosis. The major-
ity of patients were tested for C. difficile using enzyme 
immunoassay (EIA) for C. difficile toxin(s) (50  %) or 
polymerase chain reaction (PCR) (49 %). For the manage-
ment of CDI, 26 patients (5.5 %) received fidaxomicin as 
monotherapy. The remaining 446 patients received met-
ronidazole (n = 55), oral vancomycin (n = 101) or a com-
bination of metronidazole plus vancomycin (290) for the 
same episode. It is unclear if the other CDI therapy were 
received as subsequent or combination therapy. Rifaxi-
min was also received by 22 patients along with fidax-
omicin and other CDI therapy. The average duration of 
inpatient fidaxomicin therapy was 6 ± 4 days. The aver-
age total length of hospital stay was 13 ± 11 days.
A total of 102 patients (average age: 68 ± 16; females: 
59  %; Caucasian: 68  %) with CDI that received fidax-
omicin were evaluated in the multicenter chart review 
study from 11 US hospitals. Hospital types were either 
academic-based teaching (n  =  7) or community-based 
non-teaching (n  =  4). Common co-morbidities in this 
cohort include hypotension (57  %), renal disease (29  %) 
and diabetes (28  %). Twenty-five patients (25  %) had 
other gastrointestinal disorders (such as chronic diarrhea 
or constipation, diverticulitis, irritable bowel syndrome, 
or ulcer disease). Twenty-one patients (21 %) had malig-
nant solid tumor and six patients (6  %) had leukemia/
lymphoma. All patients had received previous CDI ther-
apy included metronidazole, vancomycin PO, or a com-
bination of metronidazole (intravenous or oral) and oral 
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vancomycin for patients with greater than or equal to two 
episodes either during a previous episode or at an earlier 
time period in the treatment course.
Fidaxomicin was a non-formulary medication at 6 
(n  =  54  %) of hospitals. A fidaxomicin use protocol or 
order set with specific criteria was implemented in two 
hospitals. In the absence of a formal protocol, two other 
hospitals reported involvement of an antimicrobial stew-
ardship pharmacist in confirming that fidaxomicin was 
utilized for recurrent CDI or in patients that have clini-
cal failure after metronidazole or oral vancomycin use. 
At most hospitals, including where fidaxomicin was non-
formulary (n =  8), fidaxomicin was restricted to a spe-
cialty consult service (Infectious diseases (ID) consult (7); 
ID or gastrointestinal (GI) consult (1)).
Fidaxomicin was used at a similar proportion for a 
patient’s first (n = 37), second (n = 32) or third or more 
(n  =  33) episode of CDI (Table  2). Out of 69 patients 
treated during an early CDI episode, 22 patients (32  %) 
had mild-to-moderate CDI and 47 patients (68  %) had 
severe CDI. Fidaxomicin at a standard dose of 200  mg 
by mouth twice daily was utilized for all patients with 
an inpatient therapy duration range of 1–28  days (aver-
age: 9 ± 4 days). Ninety-nine of 102 patients were initi-
ated on fidaxomicin as an inpatient, of which 22 patients 
were in the ICU. The three patients that received out-
patient fidaxomicin therapy received other CDI therapy 
while in the hospital. Total of 48 patients (47 %) received 
concomitant non-CDI antibiotics. Concomitant PPIs 
were utilized by 47 % (n = 48), H2-receptor antagonists 
by 15 % (n = 15), and immunosuppressant agents by 18 % 
(n =  18). Thirteen patients (13  %) received fidaxomicin 
monotherapy for the episode of CDI and 88 patients 
received other CDI therapy for the same episode in 
which they received fidaxomicin. Out of 88 patients, 48 
patients received subsequent therapy, 16 received sub-
sequent and combination therapy, and 4 received com-
bination therapy. For the remaining 20 patients, type of 
therapy was not able to be determined from the medical 
chart. Among patients that received subsequent or sub-
sequent and combination CDI therapy, 15 patients were 
initiated on fidaxomicin and 49 patients were initiated on 
metronidazole (n = 8), oral vancomycin (n = 14) or oral 
vancomycin plus metronidazole (n =  27). Subsequently, 
these patients were either switched to another CDI agent 
or a combination therapy, including fecal transplantation 
in two patients. Total of four patients received combina-
tion therapy in which other CDI therapy was started at 
the same time as fidaxomicin.
The length of hospital stay ranged from 1 to 90  days 
(mean  ±  SD: 19  ±  19  days). Clinical outcomes strati-
fied by CDI episode number are found in Table  3. The 
overall clinical cure rate was 77.4  % (n  =  79). Specifi-
cally, the cure rate was 68  % for patients with CDI epi-
sode 1, 77 % for patients with CDI episode 2, and 88 % 
with CDI episode 3 or greater. Forty-four of 49 patients 
Table 1 Fidaxomicin utilization rates
CDI Clostridium difficile infection, FDX fidaxomicin











Fidaxomicin utilization from third quarter of 2011 to second quarter of 2013
 Number of CDI patients 5098 5582 5160 6084 21,924
 Number of patients who received FDX 11 119 126 218 474
 FDX use rate 0.22 % 2.1 % 2.4 % 3.6 % 2.16 %
West Mid-West South Northeast
Fidaxomicin utilization rates stratified by regions in the United States
 Number of CDI patients per region 3143 5050 9026 4705
 Number of patients who received FDX per region 79 105 200 90
 Overall FDX use rates per region* 2.51 % 2.08 % 2.21 % 1.91 %
Hospital location Hospital type




Fidaxomicin utilization rates stratified by hospital location or hospital type
 Number of CDI patients per hospital location or type 2577 19,347 9304 12,620
 Number of patients who received FDX per hospital location or type 38 436 187 287
 Overall FDX use rates per hospital location or type* 1.47 % 2.25 %** 2 % 2.27 %^
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(90 %) that completed therapy with fidaxomicin only had 
clinical cure compared to 19 of the 33 patients (57.6 %) 
that completed therapy with another CDI therapy or a 
combination that included fidaxomicin with another CDI 
antibiotic. The recurrence rate within 90-days after initia-
tion of fidaxomicin and after the initial resolution of CDI 
episode was 21  % (n =  21), which included six patients 
with episode 1, seven patients with episode 2, and eight 
patients with episode 3 or greater. Thirty-two of 102 
patients were re-hospitalized within 90-days of receiv-
ing fidaxomicin (episode 1: 28 %; episode 2: 41 %; episode 
≥3: 31 %). Among the patients that were re-hospitalized, 
14 of 32 patients had documented CDI recurrence during 
the re-hospitalization. Eight of 102 patients died within 
90 days of receiving fidaxomicin (Episode 1: four patients; 
episode 2: four patients). Three patients died within 
7 days, two died within 21 days, and three died between 
30 and 90 days after fidaxomicin initiation.
For patients that required treatment for a further epi-
sode of CDI, a number of treatment strategies were used. 
Fidaxomicin use was given for further CDI episodes for 
16 patients of whom 13 received one further treatment 
course and 3 received two further courses. For these fur-
ther treatment courses, fidaxomicin was given as mono-
therapy (n =  5), as subsequent therapy or combination 
therapy with metronidazole or oral vancomycin (n = 7), 
or fidaxomicin followed by vancomycin taper (n  =  2), 
or fecal microbiota transplantation (n = 2). Further epi-
sodes that did not contain fidaxomicin were generally 
oral vancomycin-based regimens.
Discussion
In 2011, fidaxomicin was approved for the treatment of 
CDI. Prior to this time, metronidazole and oral vanco-
mycin had been the mainstays of therapy. Despite dem-
onstrating decreased CDI recurrence rates compared to 
vancomycin, fidaxomicin use was generally thought to be 
low likely due to a high drug acquisition price and per-
haps due to an under-recognition of the importance of 
recurrent CDI (Aitken et al. 2014). This study is the first, 
nationally representative trial to assess global fidaxomicin 
use throughout the USA. Using the Premier Perspective 
Database, it was demonstrated that fidaxomicin use has 
increased slowly but steadily since its introduction with 
no specific area of the country or hospital type adopt-
ing increased fidaxomicin use more than others. Using 
a multicenter, medical chart review study, it was demon-
strated that fidaxomicin is used somewhat equivalently 
based on CDI episodes but is almost universally associ-
ated with either other CDI antibiotics or other non-CDI 
systemic antibiotics. This scattered use may be explained 
by non-formulary status of fidaxomicin, hospitals reserv-
ing this drug for a certain patient populations, or lack of 
guidance from the clinical practice guidelines (Cohen 
et  al. 2010; Bauer et  al. 2009). However, optimal use of 
this narrow-spectrum antibiotic is likely diminished by 
use of other antimicrobials that kill microbiota (Mullane 
Table 2 Fidaxomicin utilization stratified by CDI episodes
CDI = Clostridium difficile infection; FDX = fidaxomicin
a For one patient: unknown if received fidaxomicin as monotherapy or with other CDI therapy









Mild-moderate CDI; n(%) 10 (27 %) 12 (37.5 %) 22 (32 %) Not applicable 22/69 (32 %)
Severe CDI; n(%) 27 (73 %) 20 (62.5 %) 47 (68 %) Not applicable 47/69 (68 %)
1. FDX monotherapy; n (%) 3 (8 %) 4 (12.5 %)a 7 (10 %) 6 (18 %) 13 (13 %)
2. Other CDI therapy; n (%) 34 (92 %) 27 (84 %) 61 (88 %) 27 (82 %) 88 (86 %)
 I. Subsequent; n 18 14 32 16 48
 II. Subsequent and combination; n 8 6 14 2 16
 III. Combination; n 2 1 3 1 4
 IV. Unable to categorize; n 6 6 12 8 20
Concomitant non-CDI antibiotics; n (%) 25 (68 %) 10 (31 %) 35 (51 %) 13 (39 %) 48 (47 %)
Table 3 Clinical outcomes stratified by CDI episodes
a Out of 32 re-hospitalizations, 14 patients had documented CDI recurrence 
during that re-hospitalization










Clinical cure 25 25 29 79 (77 %)
Recurrent CDI 6 7 8 21 (21 %)
Re-hospitalizationa 9 13 10 32 (31 %)
Mortality 4 4 0 8 (8 %)
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et al. 2011). These results provide immediate opportunity 
to antimicrobial stewardship efforts to optimize use of 
fidaxomicin. Strengths of the study include a combina-
tion of a large, nationally representative database along 
with a multicenter, chart review study that included aca-
demic and community-based hospitals.
The majority of patients in this study (86 %) received 
other CDI therapy for the management of the same CDI 
episode in which fidaxomicin was used. A high rate of 
receipt of other CDI therapy has been previously shown 
in other real-world fidaxomicin studies. Despite having 
a specific guideline for use, Eiland et  al. reported that 
13 of 60 (22  %) patients received other CDI therapy 
during the same episode specifically sequential ther-
apy of metronidazole followed by fidaxomicin (13.3  %) 
or a combination therapy of metronidazole plus fidax-
omicin (8.3 %) (Eiland et al. 2015). Vargo et al. studied 
61 patients that received fidaxomicin (severe CDI: 31 %; 
recurrent CDI: 53  %), of whom the majority (>50  %) 
received fidaxomicin therapy in a combination with at 
least one other CDI therapy usually as sequential ther-
apy after receiving another CDI therapy (Vargo et  al. 
2014). In a small case series of 15 transplant patients 
that received fidaxomicin (recurrent CDI: 40  %), 7 
patients (47 %) received fidaxomicin as salvage therapy 
after receiving metronidazole, oral vancomycin, or both 
(Clutter et  al. 2013). These results agree well with our 
findings in which the majority of patients also received 
other CDI antibiotics during the same treatment epi-
sode. Although the reasons for this high rate of use of 
other CDI antibiotics during the same treatment epi-
sode is unclear, it can be posited that this may be due to 
a difficult to treat patient population in which treatment 
options are limited and perhaps due to an underappre-
ciation of the importance of a healthy microbiota for the 
sustained treatment of CDI.
Clinical response and recurrence rates in this study 
also agree with smaller case series. Unlike previous 
studies, in this current study, we stratified patients by 
severity based on the method suggested by Zar et  al. 
based on previous studies that baseline or premor-
bid creatinine may not be available for many patients; 
a requisite for severity stratification using the SHEA/
IDSA guidelines (Cohen et  al. 2010; Zar et  al. 2007; 
Shah et  al. 2013). In an evaluation of 50 patients that 
received fidaxomicin for salvage therapy (severe CDI: 
26  %; severe, complicated: 22  %; recurrent CDI: 54  %; 
concomitant, non-CDI antibiotics: 72  %) (Penziner 
et  al. 2015) the clinical cure rate was 64  % (Penziner 
et al. 2015). In a smaller observational study of 15 trans-
plant patients, the clinical cure rate was 67  % (Clutter 
et al. 2013). Two other similar case series demonstrated 
clinical cure rate that ranged from 72 to 97  % (Eiland 
et al. 2015; Vargo et al. 2014). These cure rates are lower 
than what was observed the phase III clinical trials and 
likely reflects a sicker patient population than what 
was enrolled in the indication trials (Louie et  al. 2011; 
Cornely et  al. 2012). These results also agree well with 
result from Mullane et al. who reported a lower clinical 
cure rate (84 %) and a higher recurrence rate (25 %) in a 
post hoc analysis of the phase III clinical trial in which 
27.5  % patients received concomitant non-CDI antibi-
otics (Mullane et  al. 2011). The recurrence rate within 
90 days after initiation of fidaxomicin treatment in our 
study was 21 % which agrees well with the study by Mul-
lane et  al. Taken together, these results provide strong 
evidence that the anti-recurrence properties of fidax-
omicin are likely negated if another broad spectrum 
antibiotic either directed towards C. difficile or other 
bacterial pathogens are included in the same treatment 
course. Investigations on novel uses of fidaxomicin such 
as taper or chase therapy are being conducted and may 
lead to more optimal use of this drug. However, we 
would suggest that concomitant use of fidaxomicin with 
broad-spectrum CDI antibiotics during the same treat-
ment course be limited and discouraged (Soriano et al. 
2014). This advice follows from two recently reported 
studies that demonstrated decreased CDI recurrence 
and subsequent re-hospitalizations following a formu-
lary change to fidaxomicin (Goldenberg et al. 2016; Gal-
lagher et al. 2015). In both of these studies, fidaxomicin 
was instituted earlier in the disease course as suggested 
monotherapy with benefits noted. It is likely that similar 
stewardship efforts will be required in these populations 
to achieve the same benefit.
This study has several limitations. This study collected 
data up to 2013 thus analyses will have to be repeated as 
fidaxomicin becomes more widely adopted. Although, 
we used a nationally representative database and a mul-
ticenter study design, we will not have identified all usage 
patterns for fidaxomicin. The retrospective chart review 
provided granular details regarding CDI therapy but 
not all data was available or may have been recorded. 
Likewise, the reasons for choice of therapy and appro-
priateness of concomitant antibiotics were not able to 
be assessed. Diagnostic test for CDI vary between sites 
making inter-site comparisons difficult. Recurrence rates 
were based on medical chart review thus patients with 
CDI recurrence that did not have this information in the 
medical chart would have been missed. However, this 
data along with previous investigations provide strong 
evidence that optimization of fidaxomicin in patients 
with CDI is required in order to get the full benefit from 
the drug. Antimicrobial stewardship programs should 
specifically target appropriate use of fidaxomicin in their 
list of priorities.
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Conclusion
This study demonstrated a slow but steady increase in 
fidaxomicin utilization over time. The majority of patients 
receive fidaxomicin with either other CDI-directed anti-
biotics or other systemic antibiotics. This likely decreases 
the effectiveness of fidaxomicin, a narrow-spectrum anti-
biotic. Antimicrobial stewardship teams should provide 
guidance on appropriate use of fidaxomicin to optimize 
therapy and assess the need to continue other antibiotics 
during CDI treatment.
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